Metformin Treatment in Type-1 Diabetes Patients
Author Information
Author(s): Søren Søgaard Lund, Lise Tarnow, Anne Sofie Astrup, Peter Hovind, Peter Karl Jacobsen, Amra Ciric Alibegovic, Ida Parving, Lotte Pietraszek, Merete Frandsen, Peter Rossing, Hans-Henrik Parving, Allan Arthur Vaag
Primary Institution: Steno Diabetes Center, Gentofte, Denmark
Hypothesis
Metformin treatment might reduce glycaemia as well as other non-glycaemic cardiovascular risk markers in patients with type-1 diabetes and persistent poor glycaemic control.
Conclusion
Adjunct metformin therapy did not improve glycaemic control after one year but was associated with reduced insulin dose and body weight.
Supporting Evidence
- Metformin did not significantly lower HbA1c levels compared to placebo.
- Total daily insulin dose decreased significantly in the metformin group.
- Body weight and hip circumference also decreased significantly with metformin treatment.
Takeaway
This study looked at whether adding metformin to insulin treatment helps people with type-1 diabetes control their blood sugar better. It found that it didn't help with blood sugar levels, but it did help reduce the amount of insulin needed and weight.
Methodology
A randomized, double-masked, parallel trial comparing metformin and placebo in 100 patients with type-1 diabetes over 12 months.
Potential Biases
Potential bias due to self-reported data on blood glucose levels during hypoglycaemic events.
Limitations
The study may not apply to patients with less severe glycaemic dysregulation or those not included in the trial.
Participant Demographics
All participants were Caucasian, with a mean age of approximately 45 years and a median diabetes duration of 25 to 30 years.
Statistical Information
P-Value
0.422
Confidence Interval
−0.19; 0.44
Statistical Significance
p=0.422
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website